Literature DB >> 6772961

The immunoglobulin mu constant region gene is expressed in mouse thymocytes.

D J Kemp, A Wilson, A W Harris, K Shortman.   

Abstract

It has been a matter of controversy whether the functional capacity of T cells to discriminate between antigens is mediated via immunoglobulin, an immunoglobulin-like molecule, or by the product(s) of unrelated genes. The progenitors of immunoglobulin-secreting cells, B cells, express membrane-bound immunoglobulin as the antigen-specific receptor on their surface. For T cells, although products of immunoglobulin heavy chain variable region genes are implicated as receptor components, there has been no compelling immunochemical evidence for participation of either immunoglobulin light chains or heavy chain constant regions (see refs 2-6 for the disparate views). Recently, using cloned immunoglobulin DNA sequences as hybridization probes, we have demonstrated that the immunoglobulin Cmu gene, but not the Cmu gene, is expressed as polyadenylated RNA in some T cell tumour (T lymphoma) cell lines. Individual T lymphoma lines yielded up to three discrete mu RNA species of different sizes (1.9, 2.2 and 3.0 kilobases), each species being different in size from the major mu RNA species present in B lymphoma cells (2.4 and 2.7 kilobases). We show here that cells from the normal mouse thymus contain mu RNA species, indistinguishable in size from those in T lymphoma cells, but contain little if any kappa RNA.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6772961     DOI: 10.1038/286168a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  14 in total

Review 1.  A transcriptional serenAID: the role of noncoding RNAs in class switch recombination.

Authors:  William T Yewdell; Jayanta Chaudhuri
Journal:  Int Immunol       Date:  2017-04-01       Impact factor: 4.823

2.  Immunoglobulin heavy chain gene rearrangement and transcription in murine T cell hybrids and T lymphomas.

Authors:  M C Züñiga; P D'Eustachio; N H Ruddle
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

3.  Transcripts of the immunoglobulin C mu gene vary in structure and splicing during lymphoid development.

Authors:  D J Kemp; A W Harris; J M Adams
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

4.  Expression of T-cell receptor alpha-chain genes in transgenic mice.

Authors:  L J Berg; B Fazekas de St Groth; F Ivars; C C Goodnow; S Gilfillan; H J Garchon; M M Davis
Journal:  Mol Cell Biol       Date:  1988-12       Impact factor: 4.272

5.  Rapid thymomas induced by Abelson murine leukemia virus.

Authors:  W D Cook
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

6.  Somatic rearrangements forming active immunoglobulin mu genes in B and T lymphoid cell lines.

Authors:  S Cory; J M Adams; D J Kemp
Journal:  Proc Natl Acad Sci U S A       Date:  1980-08       Impact factor: 11.205

7.  Rearrangement of immunoglobulin heavy chain genes in human T leukaemic cells shows preferential utilization of the D segment (DQ52) nearest to the J region.

Authors:  S Mizutani; A M Ford; L M Wiedemann; L C Chan; A J Furley; M F Greaves; H V Molgaard
Journal:  EMBO J       Date:  1986-12-20       Impact factor: 11.598

8.  Cell lineage specificity of chromatin configuration around the immunoglobulin heavy chain enhancer.

Authors:  A M Ford; S M Watt; A J Furley; H V Molgaard; M F Greaves
Journal:  EMBO J       Date:  1988-08       Impact factor: 11.598

9.  Expression of T cell antigen receptor and immunoglobulin genes in lymphoid organs visualized by in situ hybridization.

Authors:  G Morahan; L Malcolm; J F Miller
Journal:  EMBO J       Date:  1987-12-01       Impact factor: 11.598

10.  Human T cell gamma genes are frequently rearranged in B-lineage acute lymphoblastic leukemias but not in chronic B cell proliferations.

Authors:  Z Chen; D Le Paslier; J Dausset; L Degos; G Flandrin; D Cohen; F Sigaux
Journal:  J Exp Med       Date:  1987-04-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.